Continued Long Term Responses to Ibrutinib plus Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

被引：0
|
作者：
Hillmen, Peter
Boucher, Rebecca H.
Webster, Nichola
Dalal, Surita
Brock, Kristian
Yates, Francesca
Sankhalpara, Chhaya
Macdonald, Donald
Fegan, Christopher
McCaig, Alison
Schuh, Anna
Pettitt, Andrew
Gribben, John G.
Patten, Piers
Devereux, Stephen
Bloor, Adrian
Fox, Christopher P.
Forconi, Francesco
Rawstron, Andrew
Hillmen, Peter
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial
    Ruhnke, Leo
    Schliemann, Christoph
    Mikesch, Jan-Henrik
    Stelljes, Matthias
    Fransecky, Lars
    Steffen, Bjoern
    Kaufmann, Martin
    Burchert, Andreas
    Rank, Andreas
    Hanoun, Maher
    Hoellein, Alexander
    Kraus, Sabrina
    Haenel, Mathias
    Schaefer-Eckart, Kerstin
    Haake, Annett
    Fiebig, Frank
    Zukunft, Sven
    Middeke, Jan Moritz
    Kunadt, Desiree
    Schetelig, Johannes
    von Bonin, Malte
    Roehnert, Maximilian Alexander
    Oelschlaegel, Uta
    Stoelzel, Friedrich
    Baldus, Claudia D.
    Serve, Hubert
    Wermke, Martin
    Bornhaeuser, Martin
    Roellig, Christoph
    BLOOD, 2023, 142
  • [42] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial
    Boccardo, F.
    Guglielmini, P.
    Bordonaro, R.
    Fini, A.
    Massidda, B.
    Porpiglia, M.
    Roagna, R.
    Serra, P.
    Orzalesi, L.
    Ucci, G.
    Rubagotti, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1546 - 1554
  • [43] 6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I plus V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL)
    Ossorio Prendes, Santiago
    Gimeno, Vicente
    Hernandez Rivas, Jose Angel
    Lopez Jimenez, Francisco Javier
    Diels, Joris
    Schioppa, Claudio
    Alfayate Lobo, Ana
    Dominguez-Lubillo, Teresa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S355 - S356
  • [44] Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
    Dreyling, Martin
    Goy, Andre
    Hess, Georg
    Kahl, Brad S.
    Hernandez-Rivas, Jose-Angel
    Schuier, Natasha
    Qi, Keqin
    Deshpande, Sanjay
    Zhu, Angeline
    Parisi, Lori
    Wang, Michael L.
    HEMASPHERE, 2022, 6 (05):
  • [45] Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors
    Oechsle, Karin
    Kollmannsberger, Christian
    Honecker, Friedemann
    Mayer, Frank
    Waller, Cornelius F.
    Hartmann, Joerg T.
    Boehlke, Ina
    Bokemeyer, Carsten
    EUROPEAN UROLOGY, 2011, 60 (04) : 850 - 855
  • [46] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Weisel, K.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez-Lopez, J.
    Chen, C. I.
    Spencer, A.
    Knop, S.
    Bahlis, N. J.
    Renner, C.
    Yu, X.
    Hong, K.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    San Miguel, J. F.
    HAEMATOLOGICA, 2014, 99 : 365 - 365
  • [47] Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial
    Trotman, Judith
    Buske, Christian
    Tedeschi, Alessandra
    Matous, Jeffrey V.
    MacDonald, David
    Tam, Constantine
    Tournilhac, Olivier
    Ma, Shuo
    Treon, Steven P.
    Oriol, Albert
    Ping, Jerry
    Briso, Eva M.
    Arango-Hisijara, Israel
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [48] Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
    F. Felizzi
    Aino Launonen
    P.-O. Thuresson
    PharmacoEconomics - Open, 2023, 7 : 37 - 46
  • [49] LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION
    Barrientos, J.
    Coutre, S.
    De Vos, S.
    Flinn, I.
    Wagner-Johnston, N.
    Schreeder, M.
    Sharman, J.
    Boyd, T.
    Rai, K.
    Leonard, J.
    Sorensen, B.
    Viggiano, A.
    Jahn, T.
    Furman, R.
    HAEMATOLOGICA, 2015, 100 : 52 - 53
  • [50] Effect of long-term ibrutinib treatment on T-cell number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation with clinical response and tumor burden up to 4-years follow-up
    Palma, Marzia
    Heimersson, Kia
    Mulder, Tom
    Mellstedt, Hakan
    Osterborg, Anders
    LEUKEMIA & LYMPHOMA, 2020, 61 : 81 - 84
12345